Novartis receives EU approval for Ilaris – InvestEgate

Study 1, a 4-week, randomized , double-blind, placebo- controlled study , involved 84 patients between the ages of 2 and 19 years with active SJIA[1],[2]. Patients were treated with either a single subcutaneous dose of Ilaris (4 mg/kg, up to 300 mg ) … Ilaris is approved for the treatment of SJIA in the US and for the symptomatic treatment of refractory acute gouty arthritis in the EU.

Read the original post:
Novartis receives EU approval for Ilaris – InvestEgate

No comments yet.

TOP